In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.

The DESTINY-Breast11 study is pitting Enhertu (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) against standard care – chemotherapy followed by THP as a pre ...

The new result follows hard on the heels of positive data with Daiichi Sankyo-partnered Enhertu (trastuzumab deruxtecan) in early-stage and advanced forms of breast cancer.

The Phase III DESTINY-Breast09 clinical trial has delivered groundbreaking results, demonstrating that ENHERTU® ...

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, first-line trastuzumab deruxtecan (T-DXd; Enhertu) combined with pertuzumab ...

Download to gain expert insights and data-driven analysis from the ASCO 2025 Annual Meeting. This report covers key ...